KCM
VKTX icon

Kennedy Capital Management’s Viking Therapeutics VKTX Stock Holding History

Kennedy Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-42,391
Closed -$1.12M – 614
2025
Q2 		$1.12M Buy
42,391
+730
+2% +$19.2K 0.03% 497
2025
Q1 		$1.01M Sell
41,661
-1,358
-3% -$42.9K 0.02% 517
2024
Q4 		$1.73M Buy
43,019
+1,058
+3% +$60.3K 0.04% 538
2024
Q3 		$2.66M Sell
41,961
-5,025
-11% -$295K 0.06% 460
2024
Q2 		$2.49M Sell
46,986
-9,185
-16% -$602K 0.05% 480
2024
Q1 		$4.61M Sell
56,171
-45,517
-45% -$2.03M 0.09% 341
2023
Q4 		$1.89M Buy
+101,688
New +$1.33M 0.04% 504

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Kennedy Capital Management's VKTX Position: Q3 2025 in Review

Kennedy Capital Management sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 42,391 shares — an estimated $1.12M sold.

Kennedy Capital Management first reported a position in VKTX in Q4 2023 and held it in 7 quarters. The position peaked at $4.61M in Q1 2024. 371 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Kennedy Capital Management reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 42,391 Viking Therapeutics shares in Q3 2025, an estimated $1.12M.
  • Kennedy Capital Management first reported a position in Viking Therapeutics in Q4 2023 and held it in 7 quarters.
  • Kennedy Capital Management's Viking Therapeutics position peaked at $4.61M in Q1 2024.
  • 371 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Kennedy Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.